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low body surface area partial-thickness burns?”
Gregory Wanner
Physician Assistant Student
December 1, 2004
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

ABSTRACT:
OBJECTIVE: To determine how the synthetic skin substitute Biobrane® compares to silver
sulfadiazine (SSD, Silvadene®) in the treatment of patients with low body surface area partial
thickness burns.
STUDY DESIGN: Systematic literature review of all English language articles of primary
studies published between February 1990 and November 2004.
DATA SOURCES: Randomized controlled trials comparing Biobrane with silver sulfadiazine
were identified from MEDLINE, The Cochrane Central Registrar of Controlled Trials, and
BioMed Central.
OUTCOMES: Measured outcomes included: healing time, length of hospital stay, amount of
pain, and development of treatment complications.
RESULTS: Three trials comparing Biobrane to silver sulfadiazine found a significantly
decreased amount of healing time in those subjects treated with Biobrane. Two of the three trials
studied and found a significantly decreased length of hospital stay and a significantly decreased
amount of pain in the Biobrane-treated subjects. Each of the three trials reported complications,
which were not significant when comparing Biobrane to SSD. After combining the studies,
calculations showed an overall decrease in the healing time, pain scores, and length of hospital
stay.
CONCLUSIONS: Evidence provided by these three trials suggests Biobrane is more effective
than silver sulfadiazine at reducing healing time, length of hospital stay, and amount of pain in
the treatment of partial-thickness thermal burn injuries. Although Biobrane does not have the
anti-bacterial effects of silver sulfadiazine, the decreased number of dressing changes with
Biobrane likely decreases pain and lessens the opportunity for wound exposure to infectious
organisms or contaminants. Two of the three studies focused primarily on pediatric patients,
however the results were similar throughout all age ranges.
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INTRODUCTION:
There are roughly 1 million burn injuries that occur each year, 700,000 of these result in visits to
the emergency department.1 In the United States, as well as much of the world, treatment of
partial-thickness burns is accomplished through the use of topical antimicrobials—one of the
most common and popular of these being silver sulfadiazine (SSD, Silvadene®). SSD treatment
usually consists of daily or twice daily dressing removal, wound debridement, and reapplication
of SSD.2,3 This process is commonly painful and time consuming for the patient or caregiver. A
potential alternative to topical antimicrobials is the use of synthetic materials such as Biobrane®
to cover the wound site.4 Biobrane is a semipermeable membrane with porcine (swine) dermal
collagen bonded to a nylon and silicon mesh.5
A systematic review was conducted to determine how Biobrane compares to SSD with use in the
treatment of low body surface area (BSA) partial-thickness (2nd degree) thermal burns.
METHODS:
Literature searches were performed using the following databases: MEDLINE (1990-2004), The
Cochrane Central Register of Controlled Trials (through 4th quarter 2004), and BioMed Central
(1997-2004). Searches were restricted to the English language and human subjects, using the
key-words: “burns,” “silver sulfadiazine,” “Biobrane,” “biocompatible materials,” “occlusive
dressings,” and “biological dressings.” All randomized controlled trials (RCT) that compared
Biobrane with SSD were attempted to be located.
Trials that were included met the following inclusion criteria: (1)-Compared Biobrane with
SSD, (2)-Randomization was used, (3)-Studied subjects with partial-thickness thermal burns less
than 20% total BSA, (4)-Studied, at minimum, healing time of burn wounds and complications.
Exclusion criteria consisted of: (1)-No randomization evident, (2)-Comparing products other

than Biobrane with SSD, (3)-Studied subjects with superficial or full thickness burns, (4)-Studied
subjects with burns greater than 20% BSA, (5)-Studied subjects with burn injuries over 48 hours
old or wounds that were grossly contaminated or obviously infected.
Each trial was reviewed for the inclusion and exclusion criteria and trial data was reviewed for
statistical significance—which was considered a p-value less than 0.05.
RESULTS:
Included Studies
Literature searches and subsequent review revealed three randomized controlled trials. The
characteristics of each included RCT study are shown in Table 1. Each of the three trials
specifically studied Biobrane and SSD in the treatment of partial-thickness burns. All three of
the studies reported wound healing times and complications of treatment. In addition, two of the
three trials studied duration of hospital stays, pain levels and the use of analgesics. Two of the
three trials focused primarily on pediatric and adolescent subjects, the third included subjects of
all ages.
The inclusion criteria for the individual studies allowed percent BSA burned to be as high as
29%; however, the mean burned BSA for each study ranged approximately between 2% and
12%. The limit of 20% burned BSA was observed for this review.
A fourth trial was excluded because it studied TransCyte®—a product that uses a biological
material derived from newborn human foreskins cultured on the Biobrane mesh—compared to
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SSD. Although this trial did show similar results as the included three, it did not specifically
study Biobrane; therefore, it was not possible to determine to what extent the results were
affected by the biological material coating the Biobrane mesh.

Table 1
Characteristics of studies included in the systematic review of Biobrane versus Silver
Sulfadiazine in the treatment of partial-thickness burns
Study
Type of Study

Barret 2000
Prospective,
Randomized Controlled
Trial (RCT)
20
Biobrane: 3.1 +/- 0.5
SSD: 3.7 +/- 0.6
(Range: Not reported)
Biobrane: 8.9 +/- 4.9
SSD: 7.8 +/- 0.9
-0-17 yrs old
-Partial-thickness burn
-Thermal or scald injury
-Burned BSA 2-29%
-Admitted within 24 hrs
-Clean, non-infected
wound

Gerding 1990
Prospective RCT

Lal 1999
Prospective RCT

64
Biobrane: 18.3 +/- 2.6
SSD: 22.1 +/- 3.5
(Range: 8 mo-79 yrs)
Biobrane: 2.0 +/- 0.3
SSD: 2.4 +/- 0.5
- >2 mo of age
-Partial-thickness burn
-Burn <24 hrs old
-Wounds with “moist,
sensate surface” and
appropriate capillary
refill

Exclusion Criteria

- >17 yrs old
-Causes other than
thermal or scalding
-Full-thickness burns
-Time to admission >24
hrs
-Contaminated or
infected wounds

Withdrawals
Interventions

0
1% SSD versus
Biobrane application

- <2 mo old
-Pregnant
-Chemical or electrical
burns
-Full-thickness burns
-Wounds >24 hrs old
-History of sulfa
sensitivity
-Gross contamination
-Treated with any
topical agent before
Emerg Dept arrival
12
1% SSD versus
Biobrane application

89
Biobrane: 2.8 +/- 0.5
SSD: 3.4 +/- 0.6
(Range: Not reported)
Biobrane: 11.8 +/- 1.1
SSD: 11.5 +/- 0.9
- <17 yrs old
-Hot fluid, non-grease
burns
nd
-Superficial 2 degree
(partial-thickness) burns
-5-25% of total BSA
-In hospital within 48 hrs
of burn injury
- >17 yrs old
-Grease burns and nonscald burns
-Burns <5% or >25%
BSA
-Appear initially to need
skin grafting
-Full-thickness burns
-Burns >48 hrs old

N-value
Age (mean yrs)*

Burn BSA (mean %) *
Inclusion Criteria

10
1% SSD versus
Biobrane application
(Note: Burns to head /
neck in SSD group were
treated with polymyxin /
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* Differences in age and total burn body surface area were not statistically significant, as reported by each study

Data Analysis
Data from each study was examined for healing times, amount of pain, length of hospital stay,
and number of complications. Two of the trials did not specifically study amount of pain and

length of hospital stay. An overall review of the outcomes from each study can be found in
Table 2.
Table 2
Overall review of outcomes from studies comparing Biobrane to SSD
Outcome
6

Healing time
Pain scores
Complications
Length of hospital stay

Barret
Decreased in Biobrane
group (p < 0.001)
Decreased in Biobrane
group (p < 0.001)
NS
Decreased in Biobrane
group (p = 0.017)

Study
2
Gerding
Decreased in Biobrane
group (p < 0.01)
Decreased in Biobrane
group (p < 0.001)
NS
---

7

Lal
Decreased in Biobrane
group (p < 0.05)
--NS
Decreased in Biobrane
group (p < 0.05)

Differences noted were all statistically significant
“---“ indicates that the study did not report or specifically study the outcome
“NS” indicates no statistically significant difference between the Biobrane and SSD groups

Healing Time
Healing time was defined relatively similarly in each of the three studies as the time required to
attain complete wound closure or re-epithelialization. One of the studies estimated wound
healing time as the midpoint between the date when wound closure was documented in the
follow-up note and the previous visit.7 After taking into account the number of subjects and
combining the mean healing times from each study, an overall mean average healing time was
attained, as well as a percentage change between the Biobrane and SSD treatments (Table 3).
Wanner, Biobrane vs SSD, Pg 5

Overall, healing times were reduced by approximately 61% in subjects treated with Biobrane.
Length of Hospital Stay
The length of hospital stay was reported in two of the three studies.6,7 The total number of
subjects were taken into account and mean lengths of stay were combined to produce an overall
mean length of hospital stay for each treatment group. The overall length of hospital stay was
reduced by approximately 48% in the Biobrane-treated group (Table 3).

Amount of Pain
Pain scores were assessed in two of the three included studies.2,6 Each of these two studies
assessed pain on a 5 level linear scale, with lower numbers correlating to less pain and higher
numbers more pain. Because the Barret6 study assessed pain on a 0 to 4 scale, and the Gerding2
study on a 1 to 5 scale, a uniform scale ranging from 1 to 5 was adopted during analysis and the
Barret scores were adjusted to reflect the change. The mean total pain scores were combined,
taking into account the number of subjects, and produced an overall mean pain score. The
overall pain scores were reduced by 54% in the group treated with Biobrane (Table 3).
Table 3
Summary from the analysis of outcomes: Biobrane versus SSD

Outcomes

# of studies

# of subjects

Treatments ( mean averages)
Biobrane
SSD

Healing Time
Hospital Stay
Pain Scores

3
2
2

151
99
72

13.2 *
2.5 *
2.1 **

21.5
5.2
3.9

Change in
Biobrane group (%)
- 61.4
- 48.2
- 54.0

* Healing time & Hospital stay are reported in days
** Pain scores are reported on a linear scale (1=least pain; 5=most pain)

Complications of Treatment:
Complications of treatment were defined as the apparent development of infection or need for
skin grafting after the treatment method had begun. Each of the three studies reported
complications. The number of complications were combined, and produced an overall
complication of treatment percentage (Table 4). Overall, 5 subjects in the Biobrane group and 4
subjects in the SSD group had complications of treatment. In the Biobrane group 7.1% of
subjects experienced a complication, whereas in the SSD group 4.9% had a complication of
treatment. For the purpose of complication analysis, Biobrane was considered the “treatment”
group and SSD was considered the “control” group. The relative risk of complication was

increased in the Biobrane group, and the absolute risk of complication was 2.2% higher in the
Biobrane treatment group. Chi-square analysis shows that the increased number of
complications in the Biobrane group is not statistically significant compared with the
complications experienced in the SSD group (p=0.33).8
It should be noted that Biobrane, compared to SSD, has the potential for a unique type of
complication: non-adherence to the wound. Two subjects in the Lal study experienced nonadherence of the Biobrane and were analyzed in the Biobrane group as intent-to-treat.7 For this
review, these two subjects were not counted as complications in the Biobrane treatment group
because infection or the need for skin grafting did not occur. Had the two non-adherence
complications been included, the number of Biobrane complications was still not statistically
significant as compared to SSD complications.
Table 4
Summary of complications comparing Biobrane to SSD

Outcome
Complications
of treatment *

# of
studies
3

# of
subjects
151

Subjects w/ Outcome (%)
Biobrane
SSD
7.1

4.9

Relative
Risk
1.45

Absolute Risk
Reduction (%)
- 2.2

* Complications were considered development of infection or need for skin grafting after beginning specific treatment
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DISCUSSION:
The findings from this review support the use of Biobrane in the treatment of partial-thickness
burns affecting a body surface area of less than 20%. Compared to silver sulfadiazine, Biobrane
appears to have a clinically significant reduction in healing time, length of hospital stay, and
amount of pain. Fewer dressing changes are necessary and the need for daily debridement of

wound sites is not necessary in patients using Biobrane—this likely has an impact on this lower
pain scores demonstrated in the Biobrane treatment group. Complications experienced between
the two groups were not significantly different in terms of number of complications. Users of
Biobrane, however, must be aware of the potential for the material to become non-adherent to
the wound—essentially making a closed wound into an open wound and likely increasing the
chance for infection.
Limitations
This review has some limitations that should be noted. Attempts to find all available data
comparing Biobrane to SSD revealed a number of studies and total number of subjects that
remains small. The included studies also focused on varying age ranges and fairly large
differences in the percent BSA burned. Therefore, this review has limited power to detect the
differences present in a specific age group or a specific percentage of BSA burned.
Each of the included trials appeared to be of fair to good quality, however there were a few
limitations noted. All three of the trials did not study each of the outcomes addressed in this
review—in fact only two of the outcomes (healing time and complications) were addressed by all
three of the included studies. Because of this, results dealing with pain scores and hospital stay
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have a smaller total sample size and likely have less ability to predict outcomes in the general
population. Only one of the three studies (Lal7) specifically mentioned how subjects who
withdrew from the study were analyzed.
Although this review suggests that Biobrane appears to reduce the healing time, length of
hospital stay, and pain level of subjects; caution must be taken in applying the results of this
review to the general population, as the results may be significantly different.

It should also be noted that the American Burn Association recommends referral of partial
thickness burns >10% BSA to a burn specialty center.1 Because a number of the subjects studied
in these trials had burns near or slightly above 10% total BSA, the transferability of results to
patients with significantly lower percent burned BSA—as may be seen and managed in a
primary care or local emergency department setting—must be interpreted cautiously.
Conclusions
Data from this review implies that Biobrane is more effective than SSD at reducing healing time,
pain scores, and length of hospital stay in patients with partial-thickness burns affecting a BSA
less that 20%. Although complications encountered with Biobrane are similar in number to
those encountered with SSD, extra care must be taken when using Biobrane to ensure adherence
of the Biobrane mesh to the wound site. In order to more accurately apply these results to the
general population, future research employing a larger sample population size and addressing a
more specific age range or size of burn wound would be beneficial.
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